Aurinia Pharmaceuticals Inc (id:6450 AUPH)
8.98 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/25/2024 9:21:23 AM)
Exchange closed, opens in 8 minutes
3.00 USD (3.00%)
-6.17 USD (-6.17%)
10.32 USD (10.32%)
57.82 USD (57.82%)
1.35 USD (1.35%)
-57.68 USD (-57.68%)
138.83 USD (138.83%)
124.50 USD (124.50%)
About Aurinia Pharmaceuticals Inc
Market Capitalization 1.29B
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
| Headquarters (address) |
118 Avenue , 14315 Edmonton T5L 4S6 AB Canada |
| Phone | 250 744 2487 |
| Website | https://www.auriniapharma.com |
| Employees | 300 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | AUPH |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 4.71 - 10.67 |
| Market Capitalization | 1.29B |
| P/E trailing | -16.63 |
| P/E forward | 16.72 |
| Price/Sale | 5.87 |
| Price/Book | 3.33 |
| Beta | 1.46 |
| EPS | 3.00 |
| EPS Canada (ID:82, base:720) | 2.18 |